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responsibility of XAbstract Simvastatin (SIM) is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor widely
used in hyperlipidemia therapy. SIM has recently been studied for its anticancer activity at doses higher
than those used for the hyperlipidemia therapy. This prompted us to study the pharmacokinetics of
high-dose SIM in cancer patients. For this purpose, an LC–MS/MS method was developed to measure
SIM and its acid form (SIMA) in plasma and peripheral blood mononuclear cells (PBMCs) obtained
from patients. Chromatographic analyte separation was carried out on a reverse-phase column using
75:25 (% v/v) acetonitrile:ammonium acetate (0.1 M, pH 5.0) mobile phase. Detection was performed
on a triple quadrupole mass spectrometer, equipped with a turbo ion spray source and operated in
positive ionization mode. The assay was linear over a range 2.5–500 ng/mL for SIM and 5–500 ng/mL
for SIMA in plasma and 2.5–250 ng/mL for SIM and 5–250 ng/mL for SIMA in cell lysate. Recovery
was458% for SIM and475% for SIMA in both plasma and cell lysate. SIM and SIMA were stable
in plasma, cell lysate and the reconstitution solution. This method was successfully applied for the
determination of SIM and SIMA in plasma and PBMCs samples collected in the pharmacokinetic
study of high-dose SIM in cancer patients.
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i’an Jiaotong University.1. Introduction
Simvastatin (SIM) is a well-established drug for the treatment
of hyperlipidemia. SIM is a prodrug administered in the
lactone form, which is converted in the liver into the active
acid form (Fig. 1). It is this active carboxylate form that
reduces cholesterol biosynthesis by competitively inhibiting
the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)lsevier B.V. All rights reserved.
Figure 1 Chemical structures of (A) simvastatin, (B) simvastatin
acid and (C) lovastatin.
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[1,2]. Additionally, statins inhibit the synthesis of other down-
stream products in the mevalonate pathway, such as the
isoprenoids [1,2]. Isoprenoids, including farnesyl pyropho-
sphate (FPP) and geranylgeranyl pyrophosphate (GGPP),
are known to be involved in important cellular processes such
as proliferation and apoptosis [3]. Thus, statins have recently
been tested for their potential use as anticancer agents. As
with all agents in this class, in vitro studies have shown that
SIM displays anticancer activity, but only at concentrations
that are higher than those observed in plasma of patients being
administered typical doses associated with the hyperlipidemia
therapy [4].
Several clinical trials were subsequently conducted to study
the safety and tolerability of high dose statin analogs, includ-
ing simvastatin, in cancer patients [5–7]. Oral statins were
found to be well tolerated at high doses with minor side
effects. In a phase I study, lovastatin (LOV) given orally at a
dose of 25 mg/kg daily was well tolerated and safe in patients
with solid tumor [6]. In the case of SIM, a phase I study in
patients with myeloma or lymphoma has shown that the
maximal tolerated dose (MTD) of SIM, given orally, is
7.5 mg/kg twice a day, which is 25-fold higher than typical
dose. The most common side effects of high dose SIM were
nausea, diarrhea, muscle weakness and myalgia [7]. However,
pharmacokinetics (PK) was not deﬁned and it is not known if
SIM plasma concentrations can reach the levels necessary for
the antitumor activity observed in vitro. In this context, we
initiated a clinical study to characterize the pharmacokinetics
of simvastatin lactone and its acid form (simvastatin acid,
SIMA) in plasma and peripheral blood mononuclear cells
(PBMCs) after oral administration of SIM at 7.5 mg/kg twice
daily in patients with recurrent and refractory chronic lym-
phocytic leukemia (CLL).
SIM has low systemic bioavailability which is attributed to
the high extraction by the liver, the main site of action for
treating hyperlipidemia. Therefore, sensitive analytical meth-
ods have previously been developed to assay both SIM and
SIMA in plasma [8–11]. The ﬁrst analytical method developed
was an LC coupled with UV detection (238 nm); nonetheless,
low sensitivity for quantitation of SIM and SIMA in biologicalﬂuids was reported [12]. Better sensitivity using UV detection was
achieved later with an LOQ of 0.5 ng/mL but with run time
428.7 min [13]. A more sensitive HPLC-FD method using 1-
bromoacetylpyrene for derivatization has been reported with an
LOQ of 0.1 ng/mL for both analytes [14]. Although this LC-FD
method is highly sensitive, sample preparation using solid phase
extraction and analyte derivatization is inconvenient and time
consuming. On the other hand, several LC–MS/MS methods
have been developed for the determination of SIM and SIMA in
biological ﬂuids which are more sensitive and speciﬁc [8–11].
These methods are coupled with either solid phase extraction
(SPE) or liquid–liquid extraction (LLE) procedures. Solid phase
extraction has yielded good recoveries for SIM but SIMA
recovery was low [15]. LLE showed better recoveries for both
SIM and SIMA compared to SPE [8,10,11]. Current analytical
methods have not been validated for the analyses of SIM and
SIMA in cell lysates. Moreover, few assays have been validated
to measure plasma concentration of SIM and SIMA at higher
levels [16–18]. Here we report the development and validation of
an LC–MS/MS method for the analysis of SIM and SIMA
human plasma and PBMCs.2. Experimental
2.1. Chemicals and reagents
SIM was purchased from Toronto Research Chemicals Inc.
(North York, Canada). Ammonium acetate (Mallinckrodt
Baker, Philipsburg, NJ, USA) and sodium hydroxide (EM
Science, Gibbstown, NJ, USA) were purchased from VWR
(West Chester, PA, USA). HPLC grade acetonitrile and
diethyl ether were obtained from Sigma-Aldrich (St Louis,
MO, USA). LOV (Alexis Biochemicals, San Diego, CA,
USA), hydrochloric acid and glacial acetic acid were from
Fisher Scientiﬁc (Fair Lawn, NJ, USA). Anhydrous ethanol
was obtained from IBI Scientiﬁc (Peosta, IA, USA). K562, a
chronic myelogenous leukemia (CML) cell line, was purchased
from ATCC (Manassas, VA, USA).2.2. LC–MS/MS instrumentation and conditions
All analyses were performed using an HPLC system consisting
of a Shimadzu LC-20AD pump and a Shimadzu SIL-20AC
VP autosampler (Shimadzu, Columbia, MD, USA). The LC
system was interfaced to an API 2000 ESI-MS/MS (Applied
Biosystems, Foster City, CA, USA). The analytical column
used was a Phenomenex Luna C18 (2.0 mm 100 mm i.d.;
2.5 mm particle size), connected to a C18 guard column
(Phenomenex C18, 2.0 mm 4 mm; 5 mm particle size). An
isocratic mobile phase was used consisting of 75:25 (% v/v)
acetonitrile:ammonium acetate (0.1 M, pH 5.0 adjusted with
acetic acid). The ﬂow rate was 0.15 mL/min under ambient
temperature. The autosampler temperature was maintained at
4 1C and the injection volume was 20 mL. The run time was
10 min. All analytes and internal standard were detected on a
triple quadrupole mass spectrometer (API 2000), equipped
with a turbo ion spray source (MDS SCIEX, Toronto,
Canada) and operating in the positive ion mode. LOV was
used as an internal standard (IS). Quantitation was performed
using multiple reaction monitoring (MRM) of precursor/
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303.3 for SIMA; and 405.2/199.3 for LOV.
The optimized source parameters for SIM, SIMA and LOV
were as follows: the nebulizer gas pressure was set at 30 psi, the
heater gas at 90 psi, the ion spray voltage was 5500 V and the
turbo heater temperature was 500 1C. The curtain gas pressure
was set at 40 psi and the collision activation dissociation
(CAD) gas at 10 psi. Lastly the entrance potential, declustering
potential, collision energy and cell exit potential applied were
set at 8.27, 14, 17 and 5.25 V for SIM, 7, 3.8, 14 and 8.5 V for
SIMA and 8.7, 12.5, 21.2 and 5.4 V for LOV, respectively. All
the parameters were controlled by the Analyst software version
1.4.2 (Applied Biosystems, Foster City, CA, USA).
2.3. Preparation of standard and quality control samples
Stock solutions of SIM, SIMA and LOV (1 mg/mL) were
prepared in ethanol. SIMA was prepared by alkaline hydrolysis
of SIM [19]. Standard working solutions of SIM and SIMA were
prepared by serial dilution of the appropriate stock solutions
with mobile phase. Standards were prepared fresh for each run
by spiking 25 mL of the appropriate working solutions of both
analytes and internal standard into 425 mL of drug free human
plasma to obtain calibration concentrations of 2.5, 5, 10, 50, 100,
250, 500 ng/mL SIM, 5, 10, 50, 100, 250, 500 ng/mL SIMA and
50 ng/mL LOV. Similar to plasma calibration standards, cell
lysate calibration standards were prepared at calibration con-
centrations of 2.5, 5, 10, 50, 80, 100, 250 ng/mL SIM, 5, 10, 50,
80, 100, 250 ng/mL SIMA and 50 ng/mL LOV. Cell lysate
matrix was prepared by lysing K562 cells in deionized water
(3 107 cells/mL) via sonication.
Plasma quality control (QC) sample concentrations were 7.5,
150 and 400 ng/mL for SIM and 15, 150 and 400 ng/mL for
SIMA. Cell lysate QC sample concentrations were 7.5, 90 and
200 ng/mL for SIM and 15, 90 and 200 ng/mL for SIMA. QC
samples were prepared using stock solutions other than those
used for calibration standards preparation. Both calibration
standards and QC samples were prepared at 4 1C in an ice bath.
2.4. Processing of plasma and cell lysate samples
All plasma and cell lysate samples were stored at 80 1C and
thawed at room temperature. A 25 mL aliquot of LOV was
added to 475 mL of plasma or cell lysate sample in
16 mm 100 mm glass test tube. The tubes then were vortexed
for 10 s. After the addition of 500 mL of ammonium acetate
buffer (0.1 M, pH 5.0), tubes were vortexed again for 1 min.
Diethyl ether (3 mL) was then added to each tube and samples
were placed on a shaker at 200 rpm for 15 min at 4 1C.
Extracted samples were centrifuged at 3000 rpm for 10 min
at 4 1C. After centrifugation, the aqueous layer was frozen by
placing the tubes in dry ice for 1 min. The organic layer was
decanted into a new 16 mm 100 mm test tube and was
evaporated till dryness at room temperature using a gentle
stream of nitrogen. The residue was reconstituted in 50 mL of
mobile phase and 20 mL was injected into the HPLC column.
2.5. Method validation
The method validation of SIM and SIMA in human plasma
and cell lysate was performed according to the FDA guidelines[20]. The assay was validated for speciﬁcity and sensitivity,
linearity, precision and accuracy, extraction recovery, matrix
effect, and stability.
2.5.1. Speciﬁcity and sensitivity
Assay speciﬁcity and sensitivity were conducted in eight
different lots of blank plasma that was either left blank or
spiked with both analytes and IS. Analytes were extracted using
the previously described extraction procedure and analyzed to
determine the extent of interference by endogenous plasma
components at the retention time of both analytes and IS. The
lowest limit of quantitation (LLOQ) was assessed in the same
plasma lots used for speciﬁcity. The determination of LLOQ
was based on the criteria that the deviation of the measured
concentrations should not be more than 20% from the nominal
concentration and that the signal to noise ratio be Z5.
2.5.2. Linearity
Linearity was evaluated using plasma samples spiked with both
SIM and SIMA at concentration ranges 2.5–500 ng/mL and
5–500 ng/mL, respectively. The internal standard, LOV, con-
centration was 50 ng/mL in all calibration standards. Three
calibration curves were prepared and analyzed by plotting area
ratios of analyte to internal standard against the concentration
of each calibration standard. The results were ﬁtted into a linear
regression model using (1/y) as a weighting factor for both SIM
and SIMA. A cell lysate calibration curve was prepared similar
to plasma calibration curve, but at concentration ranges
2.5–250 ng/mL and 5–250 ng/mL for SIM and SIMA, respectively.
2.5.3. Precision and accuracy
The intra-day precision and accuracy was evaluated at three
different QC levels (low, medium and high) in eight replicates on
the same day and in ﬁve replicates on three different days for
inter-day precision and accuracy determination. Acceptable devia-
tion was set within 15% of the nominal concentration for accuracy
and within 15% relative standard deviation for precision.
2.5.4. Extraction recovery and matrix effect
The recovery efﬁciency of the extraction procedure was
performed at low and high QCs using the extraction procedure
described in Section 2.4. Recovery was evaluated as a
percentage of the peak area of analytes that were spiked into
a matrix before extraction to the peak area of analytes that
had been spiked after extraction of a blank matrix. Endogen-
ous substances present in the biological matrix can possibly
enhance or suppress analyte ionization to affect the sensitivity,
precision or accuracy of the described method. The matrix
effect was assessed as a percentage of the peak areas of control
plasma extracted and then spiked with analyte, to neat
standards injected directly in the same reconstitution solvent.
The matrix effect was carried out on ﬁve different lots of blank
plasma and at low and high QC levels.
2.5.5. Stability
The short term and long term stability of SIM and SIMA in
plasma and cell lysate samples was evaluated under different
storage conditions. All stability experiments were performed
at low and high QC levels. Both analytes were spiked
individually in order to assess the potential for interconversion
between the lactone and acid forms.
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plasma and cell lysate samples at 4 1C (ice-bath) for 6 h. The
autosampler storage stability was determined by storing the
reconstituted QC samples for 6 h under autosampler condi-
tions (i.e., 4 1C). Samples were stored for a month at 80 1C
to evaluate long term stability of SIM and SIMA. Lastly, the
stability of SIM and SIMA in plasma and cell lysate samples
was assessed after repeated cycles of freeze and thaw (2 cycles).
In each cycle the samples were removed from 80 1C storage
and allowed to thaw at room temperature.
2.6. Pharmacokinetic study
In a pilot clinical trial, patients received an oral dose of
7.5 mg/kg SIM twice daily for one week. Only patients who
signed a written consent form were enrolled in this study.
Blood samples (8 mL) were collected after the ﬁrst oral dose of
SIM at pre-dose, 0.25, 1, 2, 3, 6, 8, and 12 h. All samples were
collected in heparinized BD Vacutainer Cell Preparation
Tubes (CPT) and immediately centrifuged (1800g for 30 min
at room temperature) to separate plasma and PBMCs.
Collected plasma and PBMCs were stored at 80 1C until
analysis. At time of analysis, PBMC pellets were thawed and
lysed in 1 mL deionized water via sonication then processed as
described in Section 2.4.3. Results and discussion:
3.1. Performance of LC and MS/MS
The Phenomenex Luna C18 column, used in this study, gave a
symmetric peak shape for all analytes with an acceptable run
time (10 min). Mobile phase components were selected based
on previous works where ammonium acetate was used to
enhance ionic strength of the analytes [9]. Also, different
volumetric ratios of acetonitrile and ammonium acetate buffer
were tested to obtain the best peak shape for both analytes
with reasonable retention time (o10 min). In previously
developed methods, SIM and LOV (Fig.1) were detected in
positive ion mode whereas negative ion mode was typically
favored for simvastatin acid detection [8,9,11]. Few studies
have utilized the positive ion mode for detecting SIM acid
[16,17]. However, in our studies simvastatin acid gave better
fragmentation in positive ion mode with higher product ion
signal intensities. Thus, both analytes (SIM and SIMA) and IS
(LOV) were detected in positive ion mode without the need to
switch polarity during the sample run. MS source parameters,
as well as analytes parameters, were optimized to achieve the
highest signal intensity.
3.2. Selectivity and sensitivity (LLOQ)
Plasma samples from eight different sources were tested for
the presence of endogenous substances that might interfere at
the retention times of peaks of interest as evaluated by
chromatograms of blank plasma and cell lysate, plasma and
cell lysate spiked with SIM and SIMA at QC1 level or LOV at
50 ng/mL, plasma and PBMCs collected from patients at
predose and 12 h after receiving SIM at 7.5 mg/kg twice daily
(Fig.2). Both SIMA and SIM were well separated withretention times of 2.65 and 7.1 min, respectively. LOV was
detected at 5.6 min. The chromatograms show no interfering
peaks at the retention times of both analytes and IS in the
blank plasma. However, in-source lactonization of SIMA into
SIM was recognized as shown in Fig.2B, where a small peak
(Peak 1) can be seen on the simvastatin MRM channel (m/z
419.3/199.3) at the retention time of SIMA. A similar peak
(Peak 2) occurs on the simvastatin acid MRM channel (m/z
437.3/303.3) at the retention time of SIM, this peak was
explained as the interference of Aþ1 isotope from [MþNH4]þ
of the SIM lactone form but not by in-source hydrolysis [21].
Therefore, chromatographic separation between SIM and
SIMA is needed to eliminate the contribution of the post
column in-source lactonization and the interference of
[MþNH4]þ isotope of simvastatin lactone.
The LLOQ was tested at different levels ranging from 1 to
10 ng/mL and it was found to be 2.5 ng/mL for SIM with an
accuracy of 97% and 8% precision while SIMA showed an
LLOQ of 5 ng/mL with 105% accuracy and 7% precision.
Previous analytical methods have proven to be highly sensitive
with a limit of quantitation ranging from 0.05 to 0.1 ng/mL
[8,9,11,16]. These methods developed for the determination of
low SIM and SIMA plasma levels achieved by typical doses
(40 mg). However, our method is developed for PK study of high
dose SIM that is 25-fold higher than typical doses, thus LLOQ
achieved was sufﬁcient for the purpose of this study.
3.3. Linearity, precision and accuracy
The calibration curves of SIM (2.5–500 ng/mL) and SIMA
(5–500 ng/mL) in human plasma and SIM (2.5–250 ng/mL) and
SIMA (5–250 ng/mL) in cell lysate showed acceptable linearity.
These ranges encompassed the concentrations observed in human
plasma and PBMCs collected in a pharmacokinetic study follow-
ing the oral administration of high dose simvastatin. Calibration
curves (n¼3) prepared in human plasma yielded the following
regression equations y¼0.005 (70.001)þ0.61(70.03)x with R2¼
0.997 and y¼0.002 (70.002)þ0.23 (70.02)x with R2¼0.997 for
SIM and SIMA, respectively. Similarly, calibration curves (n¼3)
prepared in cell lysate yielded the following regression equations
y¼0.003 (70.002)þ0.65 (70.11)x with R2¼0.997 and y¼0.001
(70.002)þ0.31 (70.09)x with R2¼0.992 for SIM and SIMA,
respectively.
Inter- and intra-day precision and accuracy were determined
at three concentration levels (7.5, 200 and 400 ng/mL for SIM
and 15, 90 and 150 ng/mL for SIMA). As shown in Table 1,
inter- and intra-day precision values of SIM and SIMA,
expressed as % relative standard deviation (RSD), ranged
from 1.1% to 5.3%, whereas accuracy values ranged between
88.6% and 110.2%. The results from intra- and inter-day
precision and accuracy indicate that the method reproducibility
is acceptable within the same day and on different days.
3.4. Recovery and matrix effect
Analytes were extracted from biological samples using a
liquid-liquid extraction procedure; several organic solvents
were tested for their extraction efﬁciencies such as methyl
tertiary butyl ether (MTBE), diethyl ether, ethyl acetate,
acetonitrile and methanol. Ethyl acetate showed fair recovery
for SIM, but extraction efﬁciency for SIMA was poor. MTBE
Figure 2 Representative chromatograms of: blank plasma (A) and cell lysate (F), plasma (B) and cell lysate (G) spiked with both SIM
and SIMA at QC1 level, plasma (C) and cell lysate (H) spiked with LOV at 50 ng/mL, patient plasma (D) and PBMCs (I) samples
collected at predose and patient plasma (E) and PBMCs (J) samples collected 12 h after oral administration of simvastatin (7.5 mg/kg).
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Table 1 Intra- and inter-day precision and accuracy.
Analyte Nominal concentration
(ng/mL)
Intra-day (n¼8) Inter-day (n¼5)
Accuracy
(mean7SD, %)
Precision
(% RSD)
Accuracy
(mean7SD, %)
Precision
(% RSD)
Simvastatin
QC1 7.5 110.275.7 5.2 96.572.5 2.6
QC2 150 105.271.4 1.4 97.172.4 2.4
QC3 400 99.672.1 2.1 94.772.3 2.4
Simvastatin acid
QC1 15 95.373.0 3.2 92.974.9 5.3
QC2 150 89.471.0 1.1 90.372.3 2.5
QC3 400 86.872.1 2.4 91.171.4 1.5
SD, standard deviation and RSD, relative standard deviation.
Table 2 Recovery and matrix effect.
Analyte Recovery (mean7SD, %)(n¼3) Absolute matrix effect
(mean7SD, %) (n¼5)
Human plasma Cell lysate
Simvastatin
QC1 75.375.8 95.774.1 98.973.3
QC3 68.675.4 67.577.6 99.075.6
Simvastatin acid
QC1 73.274.4 98.175.8 96.473.9
QC3 58.974.1 63.8710.1 98.771.0
SD, standard deviation.
T.A. Ahmed et al.408and diethyl ether were found to have comparable extraction
efﬁciencies for both SIM and SIMA and were higher than
those obtained by the other organic solvents used. Although
MTBE was commonly used in previous methods, diethyl ether
was chosen for LLE procedure in this study. Mean recovery
values of SIM and SIMA in human plasma were found to be
75.3% and 73.2% at QC1 level whereas at QC3 level they were
68.6% and 58.9%, respectively. In cell lysate, mean recovery
of SIM and SIMA were higher at QC1 levels compared to
plasma recovery with 95.7% and 98.1%, respectively. Recov-
ery values of both SIM and SIMA in cell lysate at QC3 level
were similar to those in human plasma. Furthermore, the
mean matrix effect values are within the acceptable range for
both SIM and SIMA, indicating that the matrix effect has no
impact on the analytes quantiﬁcation. The results of the
recovery and matrix effect are summarized in Table 2.3.5. Stability
The interconversion between SIM and SIMA is a result of
hydrolysis of SIM and lactonization of SIMA. It has been found
that the interconversion can be reduced either at low temperature
or when pH is adjusted between pH 4 and pH 5 [15]. Acidiﬁed
samples stored under low temperature conditions display very
low interconversion (o1% at 4 1C and 0.05% at 20 1C for four
weeks) [15]. Thus, during method validation, the plasma and cell
lysate samples were kept at 4 1C at all stages of analysis and the
reconstitution solution was buffered at pH 5. As shown inTable 3, SIM and SIMA were found to be stable in human
plasma, cell lysate and the buffered reconstitution solution for at
least 6 h at 4 1C. For long term stability, both analytes were stable
in human plasma and cell lysate for at least one month at 80 1C
(Table 4). Over two freeze–thaw cycles of human plasma and cell
lysate, SIM and SIMA were also found to be stable (Table 5).
Stability of SIM and SIMA in stock and working solutions
has been tested in several previous works. Over different
solutions compositions both SIM and SIMA were found to
be stable for at least one month [8,11,15,16]. However, we
have tested the stability of both SIM and SIMA in working
solution kept at 80 1C, and they were found to be stable for
at least one year. Lastly, no stability studies were carried out
for LOV as it has previously been shown to be stable under
similar storage conditions [22].3.6. Pharmacokinetic study
This method was successfully applied for the determination of
SIM and SIMA in human plasma and PBMCs samples
collected from leukemia patients following the oral adminis-
tration of high dose simvastatin. Fig.2 shows the MRM
chromatograms of both plasma and PBMCs samples collected
from a patient 12 h after receiving SIM at 7.5 mg/kg twice
daily. Fig.3 depicts a typical pharmacokinetic proﬁle of SIM
and SIMA in plasma and SIM in PBMCs from a CLL patient
who received high dose simvastatin. Unlike SIM, SIMA
concentrations in PBMCs were below the detection limit of
Table 3 Short term stability of the analytes in mobile phase extract, human plasma and cell lysate stored at 4 1C (n¼3).
Analyte Analyte concentrations at different time points (mean7SD)a
Mobile phase extract Human plasma Cell lysate
1 h 3 h 6 h 1 h 3 h 6 h 1 h 3 h 6 h
Simvastatin
QC1 99.776.7 106.7711.8 102.7710.2 96.674.0 99.8714.4 101.978.8 118.9711.7 121.9721.6 109.9710.7
QC3 100.372.4 101.072.9 97.972.8 94.074.7 113.573.0 115.770.6 97.1712.0 110.4711.8 97.378.6
Simvastatin acid
QC1 101.274.6 89.673.2 92.873.7 85.5724.6 94.578.5 102.8713.5 121.0716.8 111.978.6 101.179.2
QC3 100.073.9 98.371.8 96.873.1 95.0710.4 97.4710.1 97.572.9 89.971.2 81.473.4 90.373.0
aAnalyte concentrations are expressed as the mean percentage of time zero concentrations 7standard deviation (SD) .
Table 4 Long term stability in human plasma and cell lysate (n¼3).
Analyte Analyte concentrations at different time points (mean7SD)a
Human plasma Cell lysate
1 day 3 days 1 week 2 weeks 4 weeks 1 day 1 week 2 weeks 4 weeks
Simvastatin
QC1 105.577.6 95.679.4 102.5710.9 99.675.2 97.076.5 99.777.8 90.279.2 98.374.8 90.575.7
QC3 112.179.4 97.373.6 102.372.6 101.4718.3 95.4711.9 87.474.4 106.578.4 99.975.2 101.679.2
Simvastatin acid
QC1 91.377.7 106.1713.4 105.9711.0 106.876.5 91.3716.4 97.175.6 104.378.7 104.573.2 114.777.1
QC3 99.177.3 106.573.6 96.772.2 106.9717.3 108.377.2 90.4714.0 96.279.4 83.0713.2 96.2712.5
aAnalyte concentrations are expressed as the mean percentage of time zero concentrations 7standard deviation (SD).
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Table 5 Freeze and thaw stability in human plasma and cell lysate (n¼3).
Analyte Analyte concentrations at given cycle (mean7SD)a
Human plasma Cell lysate
1st cycle 2nd cycle 1st cycle 2nd cycle
Simvastatin
QC1 113.9711.8 103.774.7 101.5710.0 95.675.1
QC3 102.975.1 104.575.1 88.776.5 100.3710.1
Simvastatin acid
QC1 85.474.9 95.1716.5 91.475.3 109.976.8
QC3 96.5711.7 90.373.3 86.176.9 105.373.3
aAnalyte concentrations are expressed as the mean percentage of time zero concentrations 7standard deviation (SD).
Figure 3 Pharmacokinetic proﬁles of (A) simvastatin lactone and
carboxylate in plasma and (B) simvastatin lactone in PBMCs after
oral administration of high dose simvastatin in a CLL patient.
simvastatin concentration in PBMCs is normalized to the protein
concentration of each PBMCs sample.
T.A. Ahmed et al.410the assay at all the time points of the PK study. This could be
attributed to the hydrophilicity of the carboxylate form which
may limit its accessibility to the PBMCs. Alternatively, the
carboxylate may be subject to efﬂux by an ATP-binding
cassette transporter.4. Conclusions
In conclusion, an LC–MS/MS was developed and validated
for the determination of simvastatin and its acid form in
human plasma and cell lysate. This assay is the ﬁrst method
developed for the analysis of SIM and SIMA in cell lysate.Moreover, this assay spans the concentration range of quanti-
ﬁcation of both SIM and SIMA that is applied for high dose
SIM administration. Overall, this analytical method has
proved to be successful for the analysis of SIM and SIMA
in plasma and PBMCs samples collected from a high dose
simvastatin pharmacokinetic study.References
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